Melinda Magyari, MD, PhD, The Danish Multiple Sclerosis Center, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark, provides an overview of current treatment guidelines and recommendations available for the management of pregnancy in multiple sclerosis and neuromyelitis optica spectrum disorders (NMOSD). In the MS space, the EMA and FDA have treatment recommendations, and several MS pregnancy registries and observational studies have provided evidence regarding the safety of some treatments and support expert recommendations. But in the case of NMOSD, there is no evidence or guidelines related to the safety of the novel monoclonal antibodies in pregnancy. However, these drugs have been used in rheumatological diseases; hence it is possible to use those recommendations for NMOSD. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2022 in Amsterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.